Talacotuzumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. Upon intravenous administration, talacotuzumab binds to and neutralizes CD123. This may inhibit IL-3-dependent signaling and may inhibit proliferation and differentiation in CD123-positive tumor cells. CSL362 contains an engineered Fc region which increases its binding affinity to Fc-gamma receptors on the surface of natural killer (NK) cells thereby initiating antibody-dependent cellular cytotoxicity (ADCC). CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness.

**Synonyms:** - Anti-IL-3 Receptor Alpha Monoclonal Antibody CSL362 - CSL 362 - CSL362 - JNJ-56022473 - JNJ56022473 - TALACOTUZUMAB